NDAORALTABLETPriority Review
Approved
Feb 2019
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
3
Data completeness
5/8 — Partial
Priority Review
EGATEN (triclabendazole) by Novartis is cytochrome p450 2c19 inhibitors [moa]. Approved for anthelmintic [epc]. First approved in 2019.
Drug data last refreshed Yesterday · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
EGATEN (triclabendazole) is an oral anthelmintic small molecule approved in 2019 for treatment of parasitic trematode infections, particularly fascioliasis. It works by inhibiting cytochrome P450 2C19, disrupting parasite metabolism and reproduction. The drug targets patients in endemic regions with limited treatment alternatives.
PeakPost-LOE
Peak lifecycle positioning suggests mature commercial execution with established field infrastructure; limited team expansion likely unless geographic expansion accelerates.
Mechanism of Action
Cytochrome P450 2C19 Inhibitors
Pharmacologic Class:
Anthelmintic
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (3)
One and Two Doses of Oxfendazole Versus a Schedule of Two Doses of Triclabendazole in Chronic Fascioliasis
Started Aug 2026
336 enrolled
Fascioliasis
Study of Safety, Tolerability and Clinical Outcomes of Egaten in Fascioliasis Patients (6 Years of Age or Older).
Started Feb 2022
301 enrolled
Fascioliasis
Compassionate Use of Triclabendazole for the Treatment of Parasites (Prior to FDA Approval; Expanded Access Program)
Parasitic Disease
Career Relevance
Working on EGATEN offers exposure to specialty infectious disease and neglected tropical disease marketing within Novartis' rare/endemic disease portfolio. The peak lifecycle stage and upcoming patent cliff (2026) make this role ideal for professionals seeking to build expertise in LOE management, geographic expansion, and access strategy in resource-limited settings.
Worked on EGATEN at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.